Company Filing History:
Years Active: 2009
Title: Chang Fa On: Innovator in Targeted Alpha Therapy
Introduction
Chang Fa On is a notable inventor based in Revesby, Australia. He has made significant contributions to the field of cancer therapy through his innovative work in radioimmunoconjugates. His research focuses on developing targeted alpha therapy, which has the potential to revolutionize cancer treatment.
Latest Patents
Chang Fa On holds a patent for "Radioimmunoconjugates for targeted alpha therapy." This invention involves a radioimmunoconjugate that comprises an alpha-emitter, such as Bi-213, linked to the monoclonal antibody C595. This innovative approach is particularly effective in treating pancreatic and prostate cancer, as well as breast and ovarian cancer. He has 1 patent to his name.
Career Highlights
Chang Fa On is associated with the European Community, as represented by the European Commission. His work has garnered attention for its potential impact on cancer treatment methodologies.
Collaborations
He has collaborated with notable professionals in the field, including Barry John Allen and Syed Rizvi. Their combined expertise contributes to the advancement of targeted therapies in oncology.
Conclusion
Chang Fa On's contributions to targeted alpha therapy exemplify the innovative spirit of modern science. His work holds promise for improving cancer treatment outcomes and showcases the importance of collaboration in research.